Geode Capital Management LLC Acquires 9,681 Shares of Femasys Inc. (NASDAQ:FEMY)

Geode Capital Management LLC raised its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 216,164 shares of the company’s stock after purchasing an additional 9,681 shares during the period. Geode Capital Management LLC owned 0.94% of Femasys worth $238,000 at the end of the most recent reporting period.

Separately, Virtu Financial LLC purchased a new position in shares of Femasys during the fourth quarter valued at approximately $25,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Price Performance

Shares of NASDAQ FEMY opened at $1.16 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. Femasys Inc. has a 1 year low of $0.86 and a 1 year high of $1.80. The company’s 50-day moving average is $1.34 and its 200 day moving average is $1.24. The stock has a market capitalization of $31.49 million, a P/E ratio of -1.43 and a beta of -2.55.

Femasys (NASDAQ:FEMY) last posted its earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.66 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. On average, sell-side analysts expect that Femasys Inc. will post -0.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Femasys in a research note on Friday, March 28th.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.